CRHvsUSANA Health Sciences

CRH and USNA stock compared: price, dividend, valuation and results, from SEC filings.

CRH (CRH) has a market value of $61.9B and USANA Health Sciences (USNA) $244M. Over the last year, with dividends, CRH moved -13.9% and USNA -30.1%. Dividend yield: CRH 1.69%, USNA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CRH$61.9B

    USNA$244M

    CRH is 254 times USNA

  • Revenue, 12 months

    CRH$39.0B

    USNA$906M

    CRH is 43 times USNA

  • Net income, 12 months

    CRH$3.6B

    USNA-$21M

  • Operating margin

    CRH13.7%

    USNA-0.4%

    14.1 points apart

  • ROIC

    CRH9.2%

    USNA-0.6%

    9.8 points apart

  • P/E

    CRH17.4

    USNA–

  • Dividend yield

    CRH1.7%

    USNA0.0%

    1.7 points apart

  • 5-year return

    CRH+109.9%

    USNA-87.1%

    197.0 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CRH+109.9%

USNA-87.1%

010020030020222023202420252026
Returns by period
PeriodCRHWith dividendsUSNAWith dividends
1 year since November 17, 2025-13.9%Price -15.3%-30.1%Price -30.1%
3 years since November 17, 2023+62.5%+17.6% a yearPrice +53.8%-71.3%-34.1% a yearPrice -71.3%
5 years since November 17, 2021+109.9%+16.0% a yearPrice +83.7%-87.1%-33.7% a yearPrice -87.1%
10 years since November 18, 2016+256.5%+13.6% a yearPrice +174.5%-78.9%-14.4% a yearPrice -78.9%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CRHCRHUSNAUSANA Health Sciences

Valuation

CRHUSNA
Valuation
Price$92.58$13.22
Market value$61.9B$244M
Enterprise value (EV)$77.0B$65M
P/E17.4–
P/E, 5-year median16.016.3
P/B2.50.5
EV/EBIT14.4–
Free cash flow yield4.1%12.1%

Results and growth

CRHUSNA
Results and growth
Revenue, 12 months$39.0B$906M
Net income, 12 months$3.6B-$21M
Free cash flow, 12 months$2.5B$30M
Earnings per share, 12 months$5.32-$1.14
Revenue growth, year on year5.3%8.3%
Revenue growth a year, past+7.7%over 5 years-4.0%over 5 years
EPS growth a year, past-47.8%over 5 years-37.0%over 5 years

Margins and returns on capital

CRHUSNA
Margins and returns on capital
Gross margin36.2%77.3%
Operating margin13.7%-0.4%
Net margin9.2%-2.3%
ROIC9.2%-0.6%
ROE15.0%-4.0%

Balance sheet

CRHUSNA
Balance sheet
Cash$5.1B$179M
Total debt$21.6B$18M
Net debt / EBITDA2.0-6.2
Interest cover6.3×-9.4×

Dividends and buybacks

CRHUSNA
Dividends and buybacks
Dividend yield1.7%–
Dividend per share, 12 months$1.56–
Dividend growth a year, past––
Buyback yield1.9%11.3%
Shareholder yield3.6%11.3%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CRH or USNA

Didn't find what you were looking for?

Ask us
Which is bigger, CRH or USANA Health Sciences?

By market value, CRH ($61.9B) is about 253.6 times USANA Health Sciences ($244M), at today's prices.

How did CRH and USNA stock do over the last 10 years?

Since November 18, 2016, CRH's price moved +174.5% and USNA's -78.9%. With dividends: CRH +256.5% (+13.6% a year), USNA -78.9% (-14.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, CRH or USNA?

The dividend yield at today's price is 1.69% for CRH and none for USANA Health Sciences. Over the last twelve months they paid $1.56 and – per share.

Which has the higher profit margins, CRH or USANA Health Sciences?

Over the last twelve months, the net margin was 9.2% for CRH and -2.3% for USANA Health Sciences, and the operating margin 13.7% and -0.4%. Revenue was $39.0B and $906M.

Which is the better investment, CRH or USANA Health Sciences?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.